The US FDA has granted accelerated approval for the use of this CD30 monoclonal antibody in treating relapsed or refractory Hodgkin's lymphoma and anaplastic large cell lymphoma.329. This evidence concerns the gene TNFRSF8 and anaplastic large cell lymphoma.